S&P 500   3,211.61 (-0.46%)
DOW   26,715.40 (-0.58%)
QQQ   258.82 (-0.80%)
AAPL   386.04 (-1.24%)
MSFT   204.08 (-1.90%)
FB   240.03 (-0.10%)
GOOGL   1,507.14 (-0.64%)
AMZN   3,016.53 (+0.25%)
NVDA   405.65 (-0.84%)
CGC   17.90 (-1.38%)
BABA   244.41 (-1.93%)
MU   50.09 (-0.83%)
GE   7.11 (-0.42%)
TSLA   1,525.25 (-1.34%)
AMD   54.54 (-1.45%)
T   30.30 (+0.97%)
ACB   12.06 (-6.29%)
F   6.84 (+1.48%)
GILD   76.16 (-0.64%)
DIS   119.38 (-1.28%)
NFLX   527.15 (+0.74%)
BAC   23.90 (-2.85%)
BA   181.23 (-3.57%)
S&P 500   3,211.61 (-0.46%)
DOW   26,715.40 (-0.58%)
QQQ   258.82 (-0.80%)
AAPL   386.04 (-1.24%)
MSFT   204.08 (-1.90%)
FB   240.03 (-0.10%)
GOOGL   1,507.14 (-0.64%)
AMZN   3,016.53 (+0.25%)
NVDA   405.65 (-0.84%)
CGC   17.90 (-1.38%)
BABA   244.41 (-1.93%)
MU   50.09 (-0.83%)
GE   7.11 (-0.42%)
TSLA   1,525.25 (-1.34%)
AMD   54.54 (-1.45%)
T   30.30 (+0.97%)
ACB   12.06 (-6.29%)
F   6.84 (+1.48%)
GILD   76.16 (-0.64%)
DIS   119.38 (-1.28%)
NFLX   527.15 (+0.74%)
BAC   23.90 (-2.85%)
BA   181.23 (-3.57%)
S&P 500   3,211.61 (-0.46%)
DOW   26,715.40 (-0.58%)
QQQ   258.82 (-0.80%)
AAPL   386.04 (-1.24%)
MSFT   204.08 (-1.90%)
FB   240.03 (-0.10%)
GOOGL   1,507.14 (-0.64%)
AMZN   3,016.53 (+0.25%)
NVDA   405.65 (-0.84%)
CGC   17.90 (-1.38%)
BABA   244.41 (-1.93%)
MU   50.09 (-0.83%)
GE   7.11 (-0.42%)
TSLA   1,525.25 (-1.34%)
AMD   54.54 (-1.45%)
T   30.30 (+0.97%)
ACB   12.06 (-6.29%)
F   6.84 (+1.48%)
GILD   76.16 (-0.64%)
DIS   119.38 (-1.28%)
NFLX   527.15 (+0.74%)
BAC   23.90 (-2.85%)
BA   181.23 (-3.57%)
S&P 500   3,211.61 (-0.46%)
DOW   26,715.40 (-0.58%)
QQQ   258.82 (-0.80%)
AAPL   386.04 (-1.24%)
MSFT   204.08 (-1.90%)
FB   240.03 (-0.10%)
GOOGL   1,507.14 (-0.64%)
AMZN   3,016.53 (+0.25%)
NVDA   405.65 (-0.84%)
CGC   17.90 (-1.38%)
BABA   244.41 (-1.93%)
MU   50.09 (-0.83%)
GE   7.11 (-0.42%)
TSLA   1,525.25 (-1.34%)
AMD   54.54 (-1.45%)
T   30.30 (+0.97%)
ACB   12.06 (-6.29%)
F   6.84 (+1.48%)
GILD   76.16 (-0.64%)
DIS   119.38 (-1.28%)
NFLX   527.15 (+0.74%)
BAC   23.90 (-2.85%)
BA   181.23 (-3.57%)
Log in

NASDAQ:RAREUltragenyx Pharmaceutical Stock Price, Forecast & News

$83.79
-1.62 (-1.90 %)
(As of 07/16/2020 01:32 PM ET)
Add
Compare
Today's Range
$82.55
Now: $83.79
$84.75
50-Day Range
$66.46
MA: $76.05
$90.00
52-Week Range
$31.99
Now: $83.79
$91.77
Volume6,775 shs
Average Volume632,311 shs
Market Capitalization$5.00 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.28
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
Read More
Ultragenyx Pharmaceutical logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RARE
CUSIPN/A
Phone415-483-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$103.71 million
Book Value$11.32 per share

Profitability

Net Income$-402,730,000.00
Net Margins-348.78%

Miscellaneous

EmployeesN/A
Market Cap$5.00 billion
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive RARE News and Ratings via Email

Sign-up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.

Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions

How has Ultragenyx Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

Ultragenyx Pharmaceutical's stock was trading at $45.35 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RARE stock has increased by 84.0% and is now trading at $83.44. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Ultragenyx Pharmaceutical?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ultragenyx Pharmaceutical.

When is Ultragenyx Pharmaceutical's next earnings date?

Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Ultragenyx Pharmaceutical.

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) issued its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($1.91) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.68) by $0.23. The biopharmaceutical company earned $36.31 million during the quarter, compared to analysts' expectations of $36.74 million. Ultragenyx Pharmaceutical had a negative net margin of 348.78% and a negative return on equity of 60.65%. The firm's revenue for the quarter was up 99.8% on a year-over-year basis. During the same quarter last year, the business earned ($1.82) EPS. View Ultragenyx Pharmaceutical's earnings history.

What price target have analysts set for RARE?

16 Wall Street analysts have issued 1-year price targets for Ultragenyx Pharmaceutical's shares. Their forecasts range from $64.00 to $91.00. On average, they anticipate Ultragenyx Pharmaceutical's stock price to reach $81.71 in the next twelve months. This suggests that the stock has a possible downside of 2.1%. View analysts' price targets for Ultragenyx Pharmaceutical.

What are Wall Street analysts saying about Ultragenyx Pharmaceutical stock?

Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock:
  • 1. According to Zacks Investment Research, "Ultragenyx witnessed growth in the demand for Crysvita for both children and adults with X-linked hypophosphatemia in the United States. The drug's performance has been impressive so far. The company is also expanding the label of the drug and filed an sBLA for the same for the treatment of tumor-induced osteomalacia. The company’s NDA for a potential approval of its third therapy, UX007, in fatty acid oxidation disorders is under review with the FDA. Ultragenyx continues to advance two gene-therapy clinical programs — DTX401 for glycogen storage disease type Ia and DTX301 for ornithine transcarbamylase deficiency. However, being a new commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses and the need for additional capital." (4/16/2020)
  • 2. Cowen Inc analysts commented, "Matinas reported 2Q19 with net loss of ($3.6M) and ended the period with $36.8M in cash on the balance sheet. The company should have runway through 2020 and through multiple catalysts; Omega-3 (OM3) asset MAT9001 and antifungal MAT2203 (amphotericin)." (8/15/2019)

Has Ultragenyx Pharmaceutical been receiving favorable news coverage?

Headlines about RARE stock have been trending somewhat negative recently, InfoTrie reports. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ultragenyx Pharmaceutical earned a coverage optimism score of -1.7 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Ultragenyx Pharmaceutical.

Who are some of Ultragenyx Pharmaceutical's key competitors?

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Gilead Sciences (GILD), Exelixis (EXEL), TG Therapeutics (TGTX), Portola Pharmaceuticals (PTLA), Sangamo Therapeutics (SGMO), AbbVie (ABBV), Crispr Therapeutics (CRSP), GALAPAGOS NV/S (GLPG), GW Pharmaceuticals PLC- (GWPH) and Intercept Pharmaceuticals (ICPT).

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the following people:
  • Emil D. Kakkis, President, Chief Executive Officer & Director
  • Wladimir Hogenhuis, Chief Operating Officer
  • Shalini Sharp, Chief Financial Officer & Executive Vice President
  • Dennis Karl Huang, Chief Technical Operations Officer & Senior VP
  • Eric Crombez, Chief Medical Officer

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.10%) and Envestnet Asset Management Inc. (0.01%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View institutional ownership trends for Ultragenyx Pharmaceutical.

Which major investors are selling Ultragenyx Pharmaceutical stock?

RARE stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, and Theodore Alan Huizenga. View insider buying and selling activity for Ultragenyx Pharmaceutical.

Which major investors are buying Ultragenyx Pharmaceutical stock?

RARE stock was purchased by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. View insider buying and selling activity for Ultragenyx Pharmaceutical.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $83.44.

How big of a company is Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical has a market capitalization of $4.98 billion and generates $103.71 million in revenue each year. The biopharmaceutical company earns $-402,730,000.00 in net income (profit) each year or ($7.36) on an earnings per share basis.

What is Ultragenyx Pharmaceutical's official website?

The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]

This page was last updated on 7/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.